As shown in Table 1, 173 patients with NSCLC were enrolled in the present study, among whom 71 (41%) tested positively for an EGFR mutation (EGFR+) and 102 (59%) were EGFR-negative (EGFR-). Here, EGFR is linked to non-small cell lung carcinoma.